439691-80-2

Basic information

• Product Name: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE
• Synonyms: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE;1-(3-Formylbenzyl)-4-methylpiperazine;4-[(4-Methylpiperazin-1-yl)methyl]benzaldehyde 97%;1-(4-Formylbenzyl)-4-methylpiperazine
• CAS NO: 439691-80-2
• Molecular Formula: C₁₃H₁₈N₂O
• Molecular Weight: 218.29
• Mol File: 439691-80-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 338.9 °C at 760 mmHg
• Flash Point: 141.3 °C
• Appearance: /
• Density: 1.099 g/cm³
• Vapor Pressure: 9.53E-05mmHg at 25°C
• Refractive Index: 1.581
• CAS DataBase Reference: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE(439691-80-2)
• EPA Substance Registry System: 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE(439691-80-2)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 439691-80-2(Hazardous Substances Data)

Usage

General Description

4-[(4-Methylpiperazin-1-yl)methyl]benzaldehyde is a chemical compound that features a benzaldehyde group, which is a type of aromatic aldehyde, attached to a methylpiperazine group. It's relatively complex structure suggests potential use in several fields, but specifics might depend on its physical and chemical properties. 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZALDEHYDE is not widely discussed or studied in existing literature, indicating it may not be widely used or may be used under different names or within mixtures. The potential hazards, toxicity and ecological impact of 4-[(4-Methylpiperazin-1-yl)methyl]benzaldehyde are also largely unknown, potentially due to lack of extensive research on this specific compound.

InChI:InChI=1/C13H18N2O/c1-14-6-8-15(9-7-14)10-12-2-4-13(11-16)5-3-12/h2-5,11H,6-10H2,1H3

Upstream product

• 125743-63-7 4-[(4-methyl-1-piperazinyl)methyl]benzonitrile 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 106261-48-7 4-(4-methylpiperazin-1-ylmethyl)benzoic acid 
• 105-07-7 4-cyanobenzaldehyde 
• 623-27-8 terephthalaldehyde, 
• 109-01-3 1-methyl-piperazine 
• 81172-89-6 terephthalaldehyde mono(diethylacetal) 
• 17201-43-3 4-cyanobenzyl bromide 
• 945762-01-6 N-methoxy-N-methyl-4-(4-methyl-piperazin-1-ylmethyl)-benzamide 
• 1571-08-0 methyl 4-formylbenzoate 
• 26496-94-6 Ethyl 4-(bromomethyl)benzoate 
• 1044872-32-3 4-(4-methyl piperazin-1-ylmethyl)-benzoic acid ethyl ester 
• 622381-65-1 (4-(4-methyl piperazin-1-ylmethyl)phenyl)-methanol 

Downstream Products

• 1044871-87-5 5,7-dimethoxy-2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one 
• 933986-40-4 1-(4-ethynylbenzyl)-4-methylpiperazine 
• 1346617-86-4 N-[2-methyl-5-(4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-1,2,3-triazol-1-yl)phenyl]-4-(pyridine-3-yl)pyrimidin-2-amine 
• 1366232-97-4 C₂₇H₃₁N₅O 
• 1177252-06-0 1-[(1-benzyl-1H-tetrazol-5-yl){4-[(4-methylpiperazin-1-yl)methyl]phenyl}methyl]-cyclobutyl-1,4-diazepane 
• 1246936-00-4 6-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-fulvene 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers

A series of quinazoline derivatives with benzylidene hydrazine carboxamide were designed and synthesised as EGFR inhibitors. Most compounds exhibited exceptional anti-proliferative activity against A549, HepG2, MCF-7 and H1975 cells. Furthermore, six compounds demonstrated excellent inhibition activity against EGFRWT with the IC50 value both less than 2 nM. Among the six compounds, 44 exhibited the strongest activity (0.4 nM) and potently inhibited EGFRL858R/T790M (0.1 μM). Excitingly, the most potent compound 14 showed excellent enzyme inhibitory activity with 6.3 nM and 8.4 nM for both EGFRWT and EGFRT790M/L858R. The result of AO single staining and Annexin V/PI staining showed that the compound 14 and 44 could induce remarkable apoptosis of A549 cells. The compound 14 arrested the cell cycle at the S phase and compound 44 arrested the cell cycle at the G0 phase in A549 cells. These preliminary results demonstrate that compound 14 and 44 may be promising lead compound-targeting EGFR.

HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF

The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib

Three novel series of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib were prepared and evaluated in vitro for their cytostatic effects against a human chronic myeloid leukemia (K562), acute myeloid leukemia (HL60), and human leukemia stem-like cell line (KG1a). The structure-activity relationship was analyzed by determining the inhibitory rate of each imatinib analog. Benzene and piperazine rings were necessary groups in these compounds for maintaining inhibitory activities against the K562 and HL60 cell lines. Introducing a trifluoromethyl group significantly enhanced the potency of the compounds against these two cell lines. Surprisingly, some compounds showed significant inhibitory activities against KG1a cells without inhibiting common leukemia cell lines (K562 and HL60). These findings suggest that these compounds are able to inhibit leukemia stem-like cells.